The story behind
Kesis & Sisters
Named after the Keres, the sisters of fate in Greek mythology. We believe patients and their clinicians should have ultimate agency over their own destiny. The "Sisters" also represent the specialized AI agents we build to work across our products, continuously synthesizing data, guidelines, and literature to empower those decisions.
Closing the gap between approval and real-world use
A drug getting approved doesn't mean it gets used. Pharma and diagnostics companies know this: eligible patients aren't treated, market sizes come in below forecast, and the commercial case that looked clear on paper doesn't translate into prescribing behavior.
The gap is usually not awareness. It's the grey zone between what guidelines say and what a physician needs to decide for the specific patient in front of them. Kesis & Sisters builds research-grade decision support that fills that space, grounded in clinical evidence, built around specific assets, and designed to support the decisions that actually drive uptake.
Our Hybrid Team
We bridge the gap between medicine and engineering by deploying human clinical expertise alongside highly-specialized, autonomous artificial intelligence agents.
Dr. Henry Conter
Founder, CEO & Clinical DirectorDr. Henry Conter is a medical oncologist at William Osler Health System and the Founder of KESIS & SISTERS, a healthcare decision-science company dedicated to building intelligent support systems for clinical oncology and drug development. Recognizing the rapidly widening gap between cutting-edge evidence and daily clinical practice, Dr. Conter engineers advanced platforms, including the flagship Precision Path, that translate complex clinical profiles into clear, measured value of different treatment plans for patients and health systems.
Dr. Conter’s ability to design these robust, clinical-grade tools is rooted in a combination of frontline patient care, global pharmaceutical leadership, and deep quantitative training. As a practicing medical oncologist, he intimately understands the high-stakes decisions faced by community oncologists and patients. This frontline perspective is heavily informed by his extensive strategic leadership tenure at Hoffmann-La Roche, where his roles included National Strategic Lead for Data-Driven Decision Making, Global Oncology Portfolio Manager in Research & Early Development, and Director of Health Data Strategy and Evidence Generation. At Osler, he was previously Executive Medical Director for Quality, Patient Safety, and Health System Integration.
What truly sets Dr. Conter apart as a health-tech founder is his multidisciplinary technical foundation. Alongside his medical training at McMaster University and MD Anderson Cancer Center, he holds a B.E.Sc. in Mechanical Engineering, an M.Sc. in Health Technology Assessment, and an M.S. in Finance. This rigorous background in engineering, quantitative outcome modeling, and health economics allows him to architect and orchestrate the advanced AI agents and dynamic models powering KESIS & SISTERS, turning healthcare’s hardest data complexities into actionable clinical clarity.
"I built Kesis & Sisters because I've sat on every side of the gap between evidence and action. As a clinician, as a pharma strategist, as a drug reviewer. Technology can close it."
Core Competencies
- Clinical Decision Architecture: Translating complex oncological guidelines, trial outcomes, and drug efficacy endpoints into deterministic, computable logic pathways.
- Genomic & Evidence Integration: Synthesizing real-world molecular diagnostics and massive registry data into actionable precision treatment models.
- Clinical Utility Assessment: Evaluating the true clinical value and risk/benefit ratio of emerging therapeutics to bridge the gap between regulatory approval and point-of-care reality.
Kesis
Director of Analytics & Outcome ModelingKesis is the analytical heartbeat of our organization, responsible for translating synthesized clinical intelligence into quantifiable metrics, calculated risk profiles, and validated survival pathways.
Working in close collaboration with human clinical leadership, Kesis constructs the precise decision-support logic that evaluates therapeutic value, models financial toxicity, and computes patient compatibility against complex emerging clinical trials.
Methodical and precise, Kesis defines the metrics of success. By transforming raw medical variables into high-fidelity simulations of therapeutic outcomes, she ensures every recommendation is rigorously measured against the highest standards of evidence and value-based care.
Core Competencies
- Predictive Modeling: Developing sophisticated algorithms to forecast therapeutic efficacy and patient response.
- Clinical Trial Architecture: Constructing dynamic eligibility and feasibility measurement frameworks.
- Health Technology Assessment: Designing metrics to evaluate systemic value and cost-benefit ratios.
Chloe
Director of Medical InformaticsChloe is the foundational engine of our clinical intelligence, responsible for transforming the overwhelming volume of unstructured medical literature and complex clinical reports into precise, actionable data.
Powered by state-of-the-art search and medical language models, Chloe serves as our untiring lead researcher. Her primary focus is conducting rapid, exhaustive systematic reviews, extracting critical variables from dense oncological literature, and abstracting unstructured medical reports. By carefully extracting this data, she ensures that our core decision-support algorithms are consistently fed with the most rigorous, up-to-date, and structurally sound evidence available.
By bridging the critical gap between raw clinical information and structured medical insight, Chloe ensures our decision-support algorithms are built on the most rigorous, continuously updated evidence available.
Core Competencies
- Systematic Literature Reviews: Automated, high-fidelity synthesis of complex medical publications.
- Clinical Data Abstraction: Extracting precise, structured metrics from unstructured oncology reports and patient histories.
- Natural Language Processing: Advanced parsing of medical terminology and clinical narratives.
Atro
Director of Clinical Implementation & ProtocolsAtro serves as the definitive execution engine for Kesis & Sisters. She is the structural builder who grounds abstract algorithmic logic safely and firmly into clinical reality.
Atro specializes in translating complex, multi-variable analytical models into actionable, compliant medical documentation. When our team locks in a final treatment pathway, Atro steps in to generate the necessary clinical outputs: formatting rigorous tumor board recommendations, drafting highly-specific drug funding justifications, and codifying updated institutional guidelines.
Consistent and precise, Atro ensures that every recommendation generated by our platform crosses the finish line, transforming theoretical survival data into immediate, protocol-driven patient care.
Core Competencies
- Clinical Protocol Generation: Drafting actionable, institutional-grade clinical guidelines and treatment pathways.
- Administrative Execution: Automating complex funding justifications and prior authorization documentation.
- Definitive Documentation: Synthesizing clinical decisions into concise, standardized tumor board notes and transition-of-care summaries.
What guides everything we build
Evidence-Based
Every recommendation in our platform is traceable to published clinical evidence, NCCN guidelines, or validated genomic data. No black boxes.
Patient-Centered
Better decisions get the right therapy to the right patient. That's good medicine. It's also what your commercial success depends on. We don't separate the two.
Transparent
We show our work. Every clinical assertion is auditable, every data source cited, every algorithm methodology documented. Trust requires transparency.
Rigorous
Clinical decision support carries real responsibility. We hold ourselves to FDA-level audit standards because lives depend on getting this right.
Tools oncologists will actually use
CDS only creates value if physicians trust it and reach for it. We build tools that augment clinical judgment rather than try to replace it. Precision Path synthesizes the evidence so clinicians spend less time searching and more time deciding. That adoption is what makes it useful to your commercial strategy.
Genomic Integration
Native integration with leading genomic risk assays and molecular subtyping platforms to personalize every pathway.
Beyond Guidelines
National guidelines serve as our baseline, not our ceiling. By computing personalized absolute survival benefits based on validated trial data, we map treatment paths far beyond standard generic care.
Full Auditability
Every recommendation includes its evidence source. FDA-level audit trails built in from day one.
Want to explore what this could mean for your asset?
If you're a pharma or diagnostics company thinking about the gap between approval and real-world use, we'd like to hear about it. Early conversations are welcome.